Related Experiment Video
Updated: May 7, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
10.9K
Hyponatremia in patients with heart failure
Theodosios D Filippatos1, Moses S Elisaf
1Theodosios D Filippatos, Moses S Elisaf, Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.
World Journal of Cardiology
|October 11, 2013
Summary
Hyponatremia, or low sodium levels, is common in heart failure patients and linked to worse outcomes. Arginine vasopressin (AVP)-receptor antagonists show promise for increasing sodium levels, but their impact on heart failure prognosis needs further study.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Hyponatremia is the most frequent electrolyte disturbance in clinical and hospitalized patients.
- Heart failure patients frequently develop hyponatremia due to neurohormonal system activation.
- Low sodium levels can cause neurological symptoms and are linked to increased morbidity and mortality in heart failure.
Purpose of the Study:
- To review the mechanisms linking heart failure and hyponatremia.
- To describe the association between hyponatremia and disease progression, morbidity, and mortality in heart failure.
- To present treatment options for hyponatremia, emphasizing arginine vasopressin (AVP)-receptor antagonists.
Main Methods:
- Literature review analyzing mechanisms, clinical associations, and treatment of hyponatremia in heart failure.
- Focus on the role and efficacy of AVP-receptor antagonists.
Main Results:
- Hyponatremia is common in heart failure and associated with poor prognosis.
- Traditional treatments like water restriction and hypertonic saline have limited effectiveness.
- AVP-receptor antagonists effectively increase sodium levels in hyponatremic patients.
Conclusions:
- Hyponatremia significantly impacts heart failure outcomes.
- AVP-receptor antagonists offer a promising therapeutic approach for hyponatremia in heart failure.
- Further research is needed to evaluate the effects of AVP-receptor antagonists on hard clinical outcomes in this patient population.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
2.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
2.0K
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
01:30Heart Failure VII: Nursing Interventions
807
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
807
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:30Heart Failure V: Medical Management
642
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
01:27Heart Failure I: Introduction
2.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
2.1K